Paper950320
CGP 9000: a new orally active, broad-spectrum cephalosporin.
Zak O and 8 others. J Antibiot (Tokyo), 1976. Cited by 28 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. CGP 9000: a new orally active, broad-spectrum cephalosporin. Papers, record 950320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950320
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Cephalosporins | Major topic |
| Animals | |
| Bacterial Infections | |
| Cephalexin | |
| Cephradine | |
| Female | |
| Lethal Dose 50 | |
| Mice | |
| Time Factors |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,447,423 | Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/7447423 | PubMed |
| 7,069,577 | Pharmacokinetics of cefroxadin (CGP 9000) in man. | J Pharmacokinet Biopharm | 1982 | https://conductscience.org/library/papers/7069577 | PubMed |
| 6,832,192 | Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis. | Eur J Clin Pharmacol | 1983 | https://conductscience.org/library/papers/6832192 | PubMed |
| 6,561,017 | In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6561017 | PubMed |
| 6,436,182 | A randomized double-blind investigation of cefroxadine (CGP 9000) versus cephalexin in urinary tract infection. | Infection | 1984 | https://conductscience.org/library/papers/6436182 | PubMed |
| 6,341,252 | Activity of cefroxadine and cephalexin in urinary tract infections: a double-blind comparative study. | Infection | 1983 | https://conductscience.org/library/papers/6341252 | PubMed |
| 3,499,115 | In vitro and in vivo antibacterial activities of T-2588, a new oral cephalosporin, compared with those of other oral beta-lactam antibiotics. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3499115 | PubMed |
| 3,310,868 | In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3310868 | PubMed |
| 718,154 | SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/718154 | PubMed |
| 533,358 | Governmental toxicology regulations: an encumbrance to drug research? | Arch Toxicol | 1979 | https://conductscience.org/library/papers/533358 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/950320
GET https://conductscience.org/api/papers/v1/950320/authors